Antisense and antigene oligonucleotides

Structure, stability and delivery

Ram I Mahato, Zhaoyang Ye, Ramareddy V. Guntaka

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Diseases are being understood and treated at an increasingly higher level of genetic order and function. Recent advances in nucleic acid-based therapeutics offer great hope in controlling sequence-specific aberrant gene expression at the level of transcription or translation. Oligonucleotides (ODNs) which control gene expression at translation levels are known as antisense ODNs, whereas those act at transcriptional levels are triplex-forming oligonucleotides (TFOs), called anti-gene strategy (Figure 19.1). There has been tremendous progress in the understanding and application of antisense ODNs since first proposed in 1978 by Zamecnik and Stephenson. A number of different ODNs have been in clinical trials against many diseases, such as human immunodeficiency virus HIV infections and cytomegalovirus (CMV) ocular infections as well as in the control of hematological disorders including Crohn’s disease. Several antisense ODN-based formulations are in clinical trials and there is already one FDA approved product for the treatment of human CMV-induced retinitis. However, triplex forming oligonucleotides (TFOs), which can inhibit gene transcription are quite promising antigene therapy for modulation of gene expression.

Original languageEnglish (US)
Title of host publicationBiomaterials for Delivery and Targeting of Proteins and Nucleic Acids
PublisherCRC Press
Pages569-600
Number of pages32
ISBN (Electronic)9780203492321
ISBN (Print)9780849323348
StatePublished - Jan 1 2004

Fingerprint

Antisense Oligonucleotides
Oligonucleotides
Gene Expression
Clinical Trials
Cytomegalovirus Retinitis
Eye Infections
Cytomegalovirus Infections
Virus Diseases
Crohn Disease
Nucleic Acids
Genes
HIV Infections
HIV
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Mahato, R. I., Ye, Z., & Guntaka, R. V. (2004). Antisense and antigene oligonucleotides: Structure, stability and delivery. In Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids (pp. 569-600). CRC Press.

Antisense and antigene oligonucleotides : Structure, stability and delivery. / Mahato, Ram I; Ye, Zhaoyang; Guntaka, Ramareddy V.

Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids. CRC Press, 2004. p. 569-600.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mahato, RI, Ye, Z & Guntaka, RV 2004, Antisense and antigene oligonucleotides: Structure, stability and delivery. in Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids. CRC Press, pp. 569-600.
Mahato RI, Ye Z, Guntaka RV. Antisense and antigene oligonucleotides: Structure, stability and delivery. In Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids. CRC Press. 2004. p. 569-600
Mahato, Ram I ; Ye, Zhaoyang ; Guntaka, Ramareddy V. / Antisense and antigene oligonucleotides : Structure, stability and delivery. Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids. CRC Press, 2004. pp. 569-600
@inbook{246dc280ef24497997020665227924d7,
title = "Antisense and antigene oligonucleotides: Structure, stability and delivery",
abstract = "Diseases are being understood and treated at an increasingly higher level of genetic order and function. Recent advances in nucleic acid-based therapeutics offer great hope in controlling sequence-specific aberrant gene expression at the level of transcription or translation. Oligonucleotides (ODNs) which control gene expression at translation levels are known as antisense ODNs, whereas those act at transcriptional levels are triplex-forming oligonucleotides (TFOs), called anti-gene strategy (Figure 19.1). There has been tremendous progress in the understanding and application of antisense ODNs since first proposed in 1978 by Zamecnik and Stephenson. A number of different ODNs have been in clinical trials against many diseases, such as human immunodeficiency virus HIV infections and cytomegalovirus (CMV) ocular infections as well as in the control of hematological disorders including Crohn’s disease. Several antisense ODN-based formulations are in clinical trials and there is already one FDA approved product for the treatment of human CMV-induced retinitis. However, triplex forming oligonucleotides (TFOs), which can inhibit gene transcription are quite promising antigene therapy for modulation of gene expression.",
author = "Mahato, {Ram I} and Zhaoyang Ye and Guntaka, {Ramareddy V.}",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780849323348",
pages = "569--600",
booktitle = "Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids",
publisher = "CRC Press",

}

TY - CHAP

T1 - Antisense and antigene oligonucleotides

T2 - Structure, stability and delivery

AU - Mahato, Ram I

AU - Ye, Zhaoyang

AU - Guntaka, Ramareddy V.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Diseases are being understood and treated at an increasingly higher level of genetic order and function. Recent advances in nucleic acid-based therapeutics offer great hope in controlling sequence-specific aberrant gene expression at the level of transcription or translation. Oligonucleotides (ODNs) which control gene expression at translation levels are known as antisense ODNs, whereas those act at transcriptional levels are triplex-forming oligonucleotides (TFOs), called anti-gene strategy (Figure 19.1). There has been tremendous progress in the understanding and application of antisense ODNs since first proposed in 1978 by Zamecnik and Stephenson. A number of different ODNs have been in clinical trials against many diseases, such as human immunodeficiency virus HIV infections and cytomegalovirus (CMV) ocular infections as well as in the control of hematological disorders including Crohn’s disease. Several antisense ODN-based formulations are in clinical trials and there is already one FDA approved product for the treatment of human CMV-induced retinitis. However, triplex forming oligonucleotides (TFOs), which can inhibit gene transcription are quite promising antigene therapy for modulation of gene expression.

AB - Diseases are being understood and treated at an increasingly higher level of genetic order and function. Recent advances in nucleic acid-based therapeutics offer great hope in controlling sequence-specific aberrant gene expression at the level of transcription or translation. Oligonucleotides (ODNs) which control gene expression at translation levels are known as antisense ODNs, whereas those act at transcriptional levels are triplex-forming oligonucleotides (TFOs), called anti-gene strategy (Figure 19.1). There has been tremendous progress in the understanding and application of antisense ODNs since first proposed in 1978 by Zamecnik and Stephenson. A number of different ODNs have been in clinical trials against many diseases, such as human immunodeficiency virus HIV infections and cytomegalovirus (CMV) ocular infections as well as in the control of hematological disorders including Crohn’s disease. Several antisense ODN-based formulations are in clinical trials and there is already one FDA approved product for the treatment of human CMV-induced retinitis. However, triplex forming oligonucleotides (TFOs), which can inhibit gene transcription are quite promising antigene therapy for modulation of gene expression.

UR - http://www.scopus.com/inward/record.url?scp=84855250749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855250749&partnerID=8YFLogxK

M3 - Chapter

SN - 9780849323348

SP - 569

EP - 600

BT - Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids

PB - CRC Press

ER -